AAV6-mediated Systemic shRNA Delivery Reverses Disease in a Mouse Model of Facioscapulohumeral Muscular Dystrophy
Open Access
- 30 November 2011
- journal article
- Published by Elsevier BV in Molecular Therapy
- Vol. 19 (11), 2055-2064
- https://doi.org/10.1038/mt.2011.153
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Facioscapulohumeral muscular dystrophy (FSHD) region gene 1 (FRG1) is a dynamic nuclear and sarcomeric proteinDifferentiation, 2011
- Gene Therapy of mdx Mice With Large Truncated Dystrophins Generated by Recombination Using rAAV6Molecular Therapy, 2011
- Low-level shRNA Cytotoxicity Can Contribute to MYC-induced Hepatocellular Carcinoma in Adult MiceMolecular Therapy, 2010
- Artificial MicroRNAs as siRNA Shuttles: Improved Safety as Compared to shRNAs In vitro and In vivoMolecular Therapy, 2009
- Muscular dystrophy candidate gene FRG1 is critical for muscle developmentDevelopmental Dynamics, 2008
- An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologiesThe EMBO Journal, 2008
- Systematic RNAi Studies on the Role of Sp/KLF Factors in Globin Gene Expression and Erythroid DifferentiationJournal of Molecular Biology, 2007
- Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathwaysNature, 2006
- RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxiaNature Medicine, 2004
- Effective expression of small interfering RNA in human cellsNature Biotechnology, 2002